yeah the only healthy male 63 year old in Russia is Putin, the rest are all dead by then. Russia has the lowest male life expectancy @ 64 placing it among the lowest 50 countries in the world in that category.
" no one has launched missles into Oil fields to prop up prices" ...whadyah call Iraq, Lybia and Syria?
As to Calgary based oil technology fracking has given N. America a new lease on domestic supply but at a much higher cost.
I'm sure those German engineers don't mind a mis-spell. A Porshe is a race car attaining break neck speeds, GERN is like my porch out front hodge podge lodge...something you sit on whilst watch the leaves turn color and fall & the pond levels go up and down till freeze up.
July 19, 2005
Biotech company Geron Corp. said Monday that it had signed a licensing deal with drug maker Merck & Co. to develop a cancer vaccine that targets an enzyme linked to tumor growth, sending Geron shares up 27%.
Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Specific terms were not disclosed.
Merck has a long history of making conventional vaccines, which prevent infection by viruses and bacteria. Cancer vaccines, by contrast, work by stimulating the immune system to attack tumor cells that are already present in the body.
The Geron vaccine targets telomerase, an enzyme that Geron said was active in most cancer cells and that allows them to grow and multiply over long periods.
"Telomerase is always found in tumor cells, so this is one of the most compelling targets against cancer," said Steve Brozak, an analyst with WBB Securities in Westfield, N.J.
Merck, which is based in Whitehouse Station, N.J., and is one of the largest U.S. drug makers, also agreed to buy equity in tiny Geron at a future date as part of Geron's next round of financing. Additional terms were not disclosed.
Merck also acquired the option to negotiate a separate deal for Geron's dendritic cell-based telomerase vaccine. That vaccine is already in early-stage human trials. Dendritic cells are immune-system cells responsible for detecting and attacking foreign matter.
Geron, which is based in Menlo Park, Calif., will receive a payment from Merck in consideration for the option. The structure and terms of an agreement for the dendritic cell vaccine will be negotiated should Merck exercise its rights under the option.
Shares of Geron closed up $2.29 at $10.89
LOOK AT THE SP STUPID!
only once have we seen SP speed up in the $6's hold'n the $5's for only 3 months. the rest of the time it's sitting in the $1's & $2's. We enjoyed a brief respite of $4 this past summer. Tell me he's been good for SP value.
magic unicorn say ....
"never stop believing...miracles are everywhere!
only use your horn , only when u have to....neigh says the unicorn
go ahead follow that rainbow to your dream
gaze on the happy tops of sun lit clouds
race the wind into your heart's content."
should have kept your money in Switzerland. The US is heading twds major correction and equities like GERN are following suit. SP has dropped over 40% since July 1
it was in the last two 8K filings, the CEO mentioned GERN's intention for an acquisition
they're holding over 30 million every night what's a million or so daily?